Search

Your search keyword '"Zuchnická, Jana"' showing total 9 results
Start Over Author "Zuchnická, Jana"
9 results on '"Zuchnická, Jana"'

1. COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group

Author

Šimkovič, Martin, Turcsányi, Peter, Špaček, Martin, Mihályová, Jana, Ryznerová, Pavlína, Maco, Mária, Vodárek, Pavel, Écsiová, Dominika, Poul, Hynek, Móciková, Heidi, Zuchnická, Jana, Panovská, Anna, Lekaa, Mohammad, Oršulová, Martina, Prchlíková, Adéla, Stejskal, Lukáš, Mašlejová, Stanislava, Brychtová, Yvona, Bezděková, Lucie, Papajík, Tomáš, Lysák, Daniel, Trněný, Marek, Smolej, Lukáš, and Doubek, Michael

Published
2023
Full Text
View/download PDF

2. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Author

Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Al-Shemari, Salem, Aurran-Schleinitz, Thérèse, Bacchiarri, Francesca, Bellido, Mar, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofia, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, Maria, Donaldson, David, Santos, Gimena Dos, Dreta, Barbara, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón-y-Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José-Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Laribi, Kamel, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, Maria, Konstantinou, Eliana, Koren-Michowitz, Maya, Kotsianidis, Ioannis, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, Lopez-Garcia, Alberto, Marquet, Juan, Martin-Rodríguez, Lucia, Maynadié, Marc, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Miras, Fatima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, Maria, Papajík, Tomas, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martin, Smirnova, Svetlana, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Tadmor, Tamar, Tomic, Kristina, Tse, Eric, Vassilakopoulos, Theodoros, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Panagiotidis, Panagiotis, Popov, Viola Maria, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine, Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2023
Full Text
View/download PDF

3. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).

Author

Špaček, Martin, Smolej, Lukáš, Šimkovič, Martin, Nekvindová, Lucie, Křístková, Zlatuše, Brychtová, Yvona, Panovská, Anna, Mašlejová, Stanislava, Bezděková, Lucie, Écsiová, Dominika, Vodárek, Pavel, Zuchnická, Jana, Mihályová, Jana, Urbanová, Renata, Turcsányi, Peter, Lysák, Daniel, Novák, Jan, Brejcha, Martin, Líkařová, Tereza, and Vodička, Prokop

Subjects
LYMPHOCYTIC leukemia, CHRONIC lymphocytic leukemia, BRUTON tyrosine kinase, MEDICAL registries, CHRONIC leukemia, RITUXIMAB
Abstract

Summary: Idelalisib (idela), a phosphatidylinositol 3‐kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). However, no randomised trials of idelalisib plus rituximab (R‐idela) versus ibrutinib have been conducted. Therefore, we performed a real‐world retrospective analysis of patients with R/R CLL treated with R‐idela (n = 171) or ibrutinib (n = 244). The median age was 70 versus 69 years, with a median of two previous lines. There was a trend towards higher tumour protein p53 (TP53) aberrations and complex karyotype in the R‐idela group (53% vs. 44%, p = 0.093; 57% vs. 46%, p = 0.083). The median progression‐free survival (PFS) was significantly longer with ibrutinib (40.5 vs. 22.0 months; p < 0.001); similarly to overall survival (OS; median 54.4 vs. 37.7 months, p = 0.04). In multivariate analysis, only PFS but not OS remained significantly different between the two agents. The most common reasons for treatment discontinuation included toxicity (R‐idela, 39.8%; ibrutinib, 22.5%) and CLL progression (27.5% vs. 11.1%). In conclusion, our data show significantly better efficacy and tolerability of ibrutinib over R‐idela in patients with R/R CLL treated in routine practice. The R‐idela regimen may still be considered a reasonable option in highly selected patients without a suitable treatment alternative. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

4. Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL)

Author

Mihalyova, Jana, Panovska, Anna, Simkovic, Martin, Turcsanyi, Peter, Spacek, Martin, Brejcha, Martin, Lysak, Daniel, Mocikova, Heidi, Pavlova, Sarka, Chrapava, Marika, Zuchnicka, Jana, Brychtova, Yvona, Vodarek, Pavel, Urbanova, Renata, Likarova, Tereza, Malcikova, Jitka, Jurkova, Tereza, Lancova, Klara, Bezdekova, Lucie, Papajik, Tomas, Baranova, Jana, Arpas, Tomas, Pospisilova, Sarka, Smolej, Lukas, and Doubek, Michael

Published
2023
Full Text
View/download PDF

5. Real‐world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO‐CLLEAR Study by the Czech CLL Study Group

Author

Panovská, Anna, primary, Němcová, Lucie, additional, Nekvindová, Lucie, additional, Špaček, Martin, additional, Šimkovič, Martin, additional, Papajík, Tomáš, additional, Brejcha, Martin, additional, Lysák, Daniel, additional, Zuchnická, Jana, additional, Novák, Jan, additional, Starostka, David, additional, Poul, Hynek, additional, Vrbacký, Filip, additional, Vodárek, Pavel, additional, Urbanová, Renata, additional, Plevová, Karla, additional, Pospíšilová, Šárka, additional, Mašlejová, Stanislava, additional, Brychtová, Yvona, additional, Koriťáková, Eva, additional, Smolej, Lukáš, additional, and Doubek, Michael, additional

Published
2020
Full Text
View/download PDF

6. Low‐dose fludarabine and cyclophosphamide combined with rituximab in the first‐line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long‐term results of project Q‐lite by the Czech CLL Study Group

Author

Smolej, Lukáš, Brychtová, Yvona, Cmunt, Eduard, Doubek, Michael, Špaček, Martin, Belada, David, Šimkovič, Martin, Stejskal, Lukáš, Zygulová, Irena, Urbanová, Renata, Brejcha, Martin, Zuchnická, Jana, Móciková, Heidi, and Kozák, Tomáš

Subjects
CHRONIC leukemia, LYMPHOCYTIC leukemia, COMORBIDITY, CHRONIC lymphocytic leukemia, CYCLOPHOSPHAMIDE, FEBRILE neutropenia
Abstract

Summary: Therapeutic options used to be very limited for treatment‐naïve elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) before the introduction of chemo‐immunotherapy. Because dose‐reduced fludarabine‐based regimens yielded promising results, the Czech CLL Study Group initiated a prospective observational study to assess safety and efficacy of low‐dose fludarabine and cyclophosphamide combined with rituximab (FCR) in elderly/comorbid patients. Between March 2009 and July 2012, we enrolled 107 patients considered ineligible for full‐dose FCR (median age, 70 years; median Cumulative Illness Rating Scale score, 5; median creatinine clearance, 69 ml/min). Notably, 77% patients had unfavourable biological prognosis [unmutated immunoglobulin heavy‐chain variable‐region gene (IGHV), 74%; deletion 17p, 9%). Fludarabine was reduced to 12 mg/m2 intravenously (iv) or 20 mg/m2 orally on days 1–3 and cyclophosphamide to 150 mg/m2 iv/orally on days 1–3. Grade 3–4 neutropenia occurred in 56% of the patients, but there were serious infections in only 15%. The median progression‐free survival was 29 months, but was markedly longer in patients with mutated IGHV (median 53 months), especially in absence of del 11q or 17p (median 74 months). Low‐dose FCR is a well‐tolerated and effective first‐line regimen for selected elderly/comorbid patients with CLL/SLL with favourable biology. The study was registered at clinicaltrials.gov (NCT02156726). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

7. External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.

Author

Smolej, Lukáš, Turcsányi, Peter, Kubová, Zuzana, Zuchnická, Jana, Mihályová, Jana, Šimkovič, Martin, Vodárek, Pavel, Krčméryová, Mária, Móciková, Heidi, Brejcha, Martin, and Špaček, Martin

Subjects
CHRONIC leukemia, LYMPHOCYTIC leukemia, LYMPHOCYTE count, SYMPTOMS, CHRONIC lymphocytic leukemia
Abstract

Summary: Most patients with chronic lymphocytic leukaemia (CLL) are nowadays diagnosed without any symptoms and do not require therapy. A prognostic score identifying patients within this large group who are at high risk of disease progression would be highly beneficial. The recently published International Prognostic Score for Early asymptomatic patients (IPS‐E) uses combination of absolute lymphocyte count (ALC) >15 × 109/l, palpable lymphadenopathy, and unmutated immunoglobulin heavy‐chain variable‐region (IGHV) gene to predict the time to first‐line therapy (TTFT). Patients at low, intermediate, and high risk had estimated 5‐year TTFT of 8%, 28%, and 61%. We performed an external validation of the IPS‐E score using an unselected, consecutive group of 130 Binet A patients. The 5‐year TTFT was 11%, 36%, and 78% (C‐statistic 0·74). Furthermore, we propose an alternative system (AIPS‐E) using cytogenetic aberrations instead of palpable lymphadenopathy. This system yielded 5‐year TTFT of 14%, 40%, and 72%. These results were externally validated in 388 Binet A patients from five Czech centres; the 5‐year TTFT was 16%, 37%, and 80% (C‐statistic 0·74). In conclusion, we have successfully validated the IPS‐E score for patients with early stage CLL. In addition, we propose a modified scoring system, the AIPS‐E, combining IGHV, fluorescence in situ hybridisation, and ALC. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

8. Ibrutinib in hematoonkology

Author

Fečková Mihályová, Jana, primary, Ďuraš, Juraj, additional, Zuchnická, Jana, additional, Kaščák, Michal, additional, and Hájek, Roman, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results